What is Dalfampridine Mims and its Role in MS Treatment?
•
4 min read
Dalfampridine, a medication known commercially as Ampyra, is a potassium channel blocker approved by the FDA in 2010 to improve walking in adults with multiple sclerosis (MS). The query "What is Dalfampridine Mims?" often arises from healthcare professionals and patients consulting the MIMS (Monthly Index of Medical Specialities) database, a common pharmaceutical reference in many countries. This article clarifies the relationship between dalfampridine and the MIMS database, explaining the drug's mechanism of action, clinical use, and safety profile.
